The study, made available online on July 16, 2026, in the Journal of Pancreatology, was conducted by researchers at The University of Texas MD Anderson Cancer Center and the Cleveland Clinic. The team reviewed the records of 388 patients who had been treated with immune checkpoint inhibitors, developed diarrhea, and underwent fecal elastase testing between 2016 and 2024. Their goal was to determine whether low fecal elastase in this setting reflects genuine exocrine pancreatic insufficiency or is simply an artifact of watery stool.

Fecal elastase-1 is a digestive enzyme secreted by the pancreas that resists degradation in the gut, making it a convenient proxy for pancreatic exocrine function. Concentrations below roughly 200 micrograms per gram of stool are conventionally interpreted as evidence of insufficiency. The test works well in chronic pancreatic disease, but it has a well-known weakness: stool water content dilutes the measured concentration. In patients with profuse watery diarrhea from any cause, elastase levels can fall into the abnormal range even when the pancreas is perfectly healthy.

That weakness is exactly what the new analysis appears to expose. Among the 388 patients, fecal elastase was low in 168 patients, or 43.3 percent, and normal in 220 patients, or 56.7 percent. On the surface, a low result in more than four in ten patients might seem to point to widespread pancreatic dysfunction. But the clinical picture told a different story. Patients with low elastase had significantly higher fecal calprotectin levels, a marker of intestinal inflammation, measuring 356.0 micrograms per gram compared with 124.9 micrograms per gram in those with normal elastase.

Fecal calprotectin is a protein released by neutrophils infiltrating the intestinal lining, and elevated levels indicate active inflammation of the gut, such as the colitis that immune checkpoint inhibitors can trigger. The correlation between low elastase and high calprotectin fits the dilution hypothesis: the more watery and inflamed the bowel, the more the stool is diluted and the lower the measured elastase concentration falls, regardless of pancreatic output. If true pancreatic insufficiency were driving the low values, one would not expect them to track so closely with markers of intestinal inflammation.

Objective assessment of the bowel reinforced this interpretation. On colonoscopy and histopathology, the rates of active inflammation were similar between the low-elastase and normal-elastase groups. In other words, patients whose stool tested low for elastase did not show a distinct pattern of pancreatic disease; they showed the same immune-related intestinal inflammation as everyone else in the cohort. The elastase result appeared to be a downstream consequence of the diarrhea rather than an independent signal of pancreatic failure.

Outcomes provided the most decisive evidence. Diarrhea remission occurred in 74.4 percent of patients with low elastase and 69.1 percent of those with normal levels, a difference small enough to be clinically inconsequential. If low elastase truly identified a separate population with pancreatic enzyme deficiency requiring enzyme replacement, those patients would be expected to follow a different course. Instead, their diarrheal trajectories were essentially the same, suggesting that the low values carried little prognostic or therapeutic meaning.

The researchers also examined pancreatic status directly. Baseline pre-existing pancreatic abnormalities were rare in the cohort and unrelated to elastase levels, which argues against occult chronic pancreatitis as a hidden explanation for the low readings. New immune checkpoint inhibitor-related pancreatic injury, however, was observed more frequently among patients with low elastase. This finding is intriguing, because checkpoint inhibitors can cause immune-mediated pancreatitis, yet even in these cases the low elastase values did not translate into the outcomes expected of true exocrine insufficiency.

Taken together, the results support a reframing of how clinicians interpret fecal elastase in patients with immune checkpoint inhibitor-related diarrhea. In this population, a low value is more likely a dilutional artifact of watery stool than evidence of genuine pancreatic enzyme failure. The authors recommend that when pancreatic disease is genuinely suspected, clinicians should consider confirmatory fecal fat testing before initiating pancreatic enzyme replacement therapy. Fecal fat quantification directly measures malabsorption of dietary fat, the functional consequence of enzyme deficiency, and is therefore less vulnerable to the dilution effects that undermine elastase measurements in watery stool.

The practical implications extend beyond a single test. Immune checkpoint inhibitor-related diarrhea is usually managed as colitis, with corticosteroids or other immunosuppressive strategies for severe cases, and enzyme replacement would add cost and complexity without addressing the underlying inflammation. By showing that low elastase does not predict worse diarrhea outcomes and does not correspond to more inflammation on endoscopy, the study encourages a comprehensive diagnostic approach rather than reflexive enzyme therapy. For the growing population of patients receiving checkpoint inhibitors worldwide, the message is that an abnormal elastase result in the context of watery diarrhea deserves scrutiny, and fecal fat testing should confirm exocrine pancreatic insufficiency before treatment is started.

Subject of Research: Fecal elastase testing in diarrhea caused by immune checkpoint inhibitors

Article Title: Low fecal elastase in immunotherapy diarrhea may reflect dilution, not pancreatic insufficiency

Article References: Low fecal elastase in immunotherapy diarrhea may reflect dilution, not pancreatic insufficiency. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: immune checkpoint inhibitors, fecal elastase, diarrhea, pancreatic insufficiency, fecal calprotectin, colitis, immunotherapy side effects, fecal fat testing, pancreatic enzyme replacement, Journal of Pancreatology, MD Anderson Cancer Center, gastroenterology

The study was conducted through active diarrhea surveillance, meaning that research staff systematically identified and recruited eligible children as they were admitted, rather than relying on retrospective records. A total of 325 hospitalized children under five were enrolled during the two-year period. Stool samples were collected within the first 48 hours of admission and stored at minus 20 degrees Celsius to preserve the genetic material of any pathogens present. From this larger cohort, 171 stool samples, representing 53 percent of enrolled cases, were randomly selected for full multipathogen testing, with 79 samples from 2017 and 92 from 2018. Selection was done by quarter and based on sufficient specimen availability, covering children with acute, persistent, watery, or bloody diarrhea.

The molecular engine of the study was the TaqMan Array Card, a compact real-time PCR platform that can probe a single stool sample for a large panel of enteric pathogens simultaneously. The laboratory work was carried out at the Wellcome Trust Research Laboratory in Vellore, India, a center with extensive experience in multipathogen diarrheal surveillance across low- and middle-income countries. The TaqMan Array Card approach relies on targeted amplification of pathogen-specific genetic sequences, with each target producing a measurable fluorescent signal as the reaction proceeds. A cycle threshold value below 40 was considered positive, a conventional cutoff that balances analytical sensitivity against the risk of detecting insignificant amounts of genetic material.

This technology matters because traditional diagnostics, such as culture for bacteria or enzyme immunoassays for viruses, typically identify only one pathogen at a time and can miss coinfections entirely. Most previous etiologic studies of pediatric diarrhea in Indonesia focused on single pathogens, which limited understanding of the broader spectrum of enteric coinfections. By screening for many viruses, bacteria, and parasites in parallel, the TaqMan Array Card revealed a microbial landscape far more complex than single-pathogen testing would suggest, capturing the full range of agents circulating in this hospitalized population.

Beyond rotavirus, the surveillance identified several other major contributors to childhood diarrheal disease in Yogyakarta. Adenovirus 40/41, the enteric adenovirus types most classically associated with pediatric gastroenteritis, was detected in 28 percent of tested samples in 2017 but only 3 percent in 2018, a striking year-to-year swing that underscores how dramatically the circulation of individual pathogens can fluctuate across seasons. Enteroaggregative Escherichia coli, or EAEC, a diarrheagenic strain of bacteria named for its characteristic stacked-brick pattern of aggregation on intestinal cells, was detected at nearly identical rates in both years, 27 percent in 2017 and 28 percent in 2018, making it the most consistently detected bacterial pathogen in the cohort.

Norovirus GII, the genogroup responsible for the majority of human norovirus outbreaks worldwide, was detected in 11 percent of samples in 2017 and 10 percent in 2018, adding another viral agent to the list of common culprits. The stability of EAEC and norovirus GII detection across both years contrasts sharply with the volatility of adenovirus 40/41, illustrating why sustained, multiyear surveillance is essential for understanding the true etiology of pediatric diarrhea. Pathogens that appear dominant in one season may recede the next, while others maintain a steady presence year after year.

One of the most consequential findings of the study concerns coinfection. Among samples in which rotavirus was detected, the overwhelming majority carried at least one additional pathogen, with coinfection present in 81 percent of rotavirus-positive samples in 2017 and 74 percent in 2018. Bacterial pathogens were the most common coinfecting agents in these rotavirus-positive samples. This pattern suggests that children hospitalized with severe diarrhea in Yogyakarta are frequently carrying multiple enteric pathogens at once, a reality that single-pathogen diagnostics would completely miss and one that complicates the interpretation of which agent is actually responsible for the illness.

The authors were careful to note an important limitation in how coinfections were handled analytically. Multiple pathogens detected in the same sample were recorded individually, but coinfections were not analyzed as a separate category. As a result, the potential contribution of coinfection to disease severity could not be fully assessed. This is a significant caveat for the field, because the mere detection of a pathogen’s genetic material does not prove it is causing disease, and when several agents are present simultaneously, attributing clinical severity to any single one becomes genuinely difficult. Future studies with larger sample sizes and dedicated coinfection analysis will be needed to untangle these relationships.

The detection of bacterial pathogens such as EAEC also carries direct implications for clinical practice and antimicrobial stewardship. Diarrheagenic E. coli strains, including EAEC and enteropathogenic E. coli, are typically managed with supportive care rather than antibiotics in young children, and knowing the local spectrum of bacterial pathogens helps clinicians avoid unnecessary antimicrobial use. The study’s findings support the need for multipathogen surveillance to guide clinical management, antimicrobial stewardship, and immunization policy, giving health authorities a clearer evidence base for deciding when laboratory testing is warranted and which pathogens deserve targeted intervention.

For rotavirus specifically, the findings arrive at a moment when vaccine impact monitoring remains a global priority. Rotavirus vaccines have dramatically reduced severe diarrheal disease in many countries, but the persistence of rotavirus as the leading detected pathogen among hospitalized children in Yogyakarta highlights the continued importance of tracking vaccine performance and coverage in Indonesia. The study’s conclusions emphasize that rotavirus remains the leading cause of hospitalization due to diarrhea in children under five in the region, and that continued monitoring of rotavirus vaccine impact is essential. As Indonesia works toward the Sustainable Development Goals related to child health, studies like this one provide the granular, pathogen-level evidence needed to direct resources where they will save the most lives.

Subject of Research: Enteric pathogens associated with diarrhea in hospitalized children under five in Yogyakarta, Indonesia

Article Title: Enteric pathogens associated with diarrhea in children under five years of age in Yogyakarta, Indonesia (2017–2018): a hospital-based surveillance study

Article References: Nirwati, H., Giri, S., Mulyani, N. S., Erlin Mulyadi, A. W., Palupi-Baroto, R., Anggraini, D., Wahab, A., & Soenarto, Y. (2026). Enteric pathogens associated with diarrhea in children under five years of age in Yogyakarta, Indonesia (2017–2018): a hospital-based surveillance study. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07875-3

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07875-3

Keywords: rotavirus, diarrhea, children under five, Yogyakarta, Indonesia, coinfection, TaqMan Array Card, enteroaggregative E. coli, norovirus, adenovirus 40/41, pediatric hospitalization, multipathogen surveillance

Acute gastroenteritis remains one of the most frequent reasons for pediatric consultation and hospitalization worldwide, particularly among children under five and in low- and middle-income countries where limited access to clean water, inadequate sanitation, and lower rotavirus vaccination coverage amplify both incidence and severity. Despite advances in oral rehydration therapy, zinc supplementation, and supportive care, diarrheal diseases continue to impose a heavy clinical and economic burden through increased healthcare utilization, caregiver strain, and impaired child growth and development. The COVID-19 pandemic further disrupted the epidemiology of pediatric gastroenteritis: circulation of major enteric pathogens declined during periods of non-pharmaceutical interventions, then resurged after restrictions eased, before gradually returning toward pre-pandemic patterns in a manner that varied by region and vaccination coverage.

The intestinal microbiota plays a central role in gut homeostasis, immune modulation, and resistance to enteric pathogens. Acute diarrheal episodes are associated with transient but sometimes profound disruptions of microbial composition, which may prolong symptoms, impair intestinal barrier function, and predispose children to recurrence. Probiotics, defined as live microorganisms that confer a health benefit when administered in adequate amounts, have been extensively studied as adjuncts to rehydration in acute infectious diarrhea. However, their effects are strain- and indication-specific, so evidence for one product cannot be extrapolated to another; each strain must be evaluated individually. This principle is precisely why the new review focused on a single, well-characterized strain rather than pooling different probiotic products.

Limosilactobacillus reuteri DSM 17938, formerly classified as Lactobacillus reuteri, is a human-derived strain developed from the parent strain ATCC 55730 by removal of two antibiotic-resistance plasmids. It has demonstrated immunomodulatory activity, antimicrobial effects through the production of reuterin, a broad-spectrum antimicrobial compound that inhibits enteropathogen growth, and supportive actions on epithelial barrier function in both experimental and clinical settings. The strain is among the most extensively studied probiotics in pediatric gastrointestinal disorders and appears, with varying strength, in international and regional guidelines. The World Gastroenterology Organization lists it among probiotics that may reduce the duration of diarrhea in acute gastroenteritis, while the ESPGHAN Special Interest Group on Gut Microbiota and Modifications suggests it may be considered alongside rehydration therapy, though this remains a conditional recommendation based on very-low-certainty evidence.

The most recent quantitative synthesis specific to this strain and indication, published in 2019, pooled four randomized controlled trials and reported a reduction in diarrhea duration of 0.87 days, with high heterogeneity and very-low certainty of evidence. Since then, additional double-blind trials have been published, including two conducted during and after the COVID-19 pandemic in emergency-department and outpatient settings outside the previously dominant European, mostly inpatient trial base. The updated review therefore aimed to incorporate these newly published trials, re-examine the magnitude and robustness of the effect in the context of changing gastroenteritis epidemiology, and strengthen the previous analysis with a full time-course of diarrhea persistence.

Methodologically, the review followed the PRISMA 2020 statement and the Cochrane Handbook, with the protocol registered in PROSPERO. Two independent reviewers performed study selection, data extraction, and risk of bias assessment using the Cochrane Risk of Bias 2 tool, which evaluates five domains including the randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported result. The search covered MEDLINE via PubMed, Embase, Scopus, and the Science Citation Index Expanded from inception to April 1, 2026, with no language or date restrictions. Random-effects models pooled mean differences and risk ratios, and the certainty of evidence was appraised via the GRADE approach. Because the DerSimonian-Laird estimator may underestimate between-study variance when the number of trials is small, the authors prespecified a sensitivity analysis using the restricted maximum likelihood estimator with the Hartung-Knapp adjustment, which yields more conservative confidence intervals under these conditions.

The six included trials were conducted in Italy, Türkiye, Poland, Paraguay, and Thailand, randomizing children aged between 3 months and 5 years. Three trials were conducted in hospitalized children and three in outpatient or emergency-department settings. Four trials were double-blind and placebo-controlled, and two were single-blind. The daily dose of the strain ranged from 1 x 10^8 to 4 x 10^8 colony-forming units, administered for 5 days in all trials except one lasting 7 days. In all trials, the probiotic was given in addition to rehydration therapy, with placebo as the comparator in four trials and no treatment in two. No trial was judged to be at high risk of bias, though five trials were rated as having some concerns, largely related to blinding of outcome ascertainment or absence of prospective registration.

Beyond the primary outcome, the review examined the proportion of children with persisting diarrhea at successive time points. The treatment effect was modest at 24 hours, with a risk ratio of 0.87, then became substantially greater at 48 hours, with a risk ratio of 0.45, and reached its maximum at 72 hours, with a risk ratio of 0.41, roughly a halving of the risk of persisting diarrhea. The benefit remained statistically significant at 96 and 120 hours, though attenuated as most children in both groups recovered. This temporal pattern suggests that any clinical benefit of the strain is concentrated in the first two to three days of illness. Two trials also showed fewer watery stools per day on days 2 and 3, while the pooled estimate for duration of hospitalization, based on only two trials, was not statistically significant. No serious or treatment-related adverse events were reported across the trials, and where adverse events were recorded, their frequency was comparable between the probiotic and control groups.

A central observation of the review is the concordance between blinding, risk of bias, and effect size. The two single-blind trials produced the largest effects, with a pooled mean difference of 0.99 days, whereas the four double-blind trials yielded approximately half the magnitude, 0.42 days, with markedly lower heterogeneity. The formal test for subgroup differences was not statistically significant, an expected limitation given only six trials, but the pattern is consistent with the well-documented tendency of unblinded trials to inflate subjective outcomes. Because diarrhea duration is a caregiver-ascertained endpoint, trials without participant blinding may be particularly vulnerable to performance and detection bias. The double-blind estimate may therefore provide a more conservative, and possibly less biased, reflection of the true effect. The authors also note that the two post-pandemic trials showed a smaller and more homogeneous effect than the pre-pandemic trials, a finding compatible with the hypothesis that a changing etiological landscape may modify probiotic efficacy, though it cannot be disentangled from differences in design, setting, and dose, and rests on only two trials.

The authors conclude that Limosilactobacillus reuteri DSM 17938 produces a small, probably genuine reduction in the duration of childhood acute gastroenteritis and a moderate reduction in diarrhea persistence at 48 to 72 hours, with a favorable safety profile, but that the effect on the primary outcome is of uncertain clinical importance and rests on very-low-certainty evidence. Future research should prioritize adequately powered, double-blind trials with systematic pathogen characterization, standardized definitions of diarrhea resolution, and intention-to-treat analysis, ideally conducted in the current post-pandemic epidemiological context. The recently proposed Probiotic Human Study Design and Reporting recommendations offer a practical framework for this purpose, emphasizing precise strain identification, transparent reporting of dose and viable count, prospective registration, prespecified standardized outcomes, and intention-to-treat analysis. Only trials of this quality will be able to establish whether the small, sub-one-day benefit suggested by the current evidence represents a reproducible and clinically meaningful effect, and to identify the subgroups in which it is most likely to matter.

Subject of Research: Probiotic strain shortens childhood diarrhea by about 16 hours, but evidence remains shaky

Article Title: Efficacy and safety of Limosilactobacillus reuteri DSM 17938 for the treatment of acute gastroenteritis in children: a systematic review and meta-analysis of randomized controlled trials

Article References: Dinleyici, E. C., Indrio, F., Gutierrez-Castrellon, P., & Rosa, D. (2026). Efficacy and safety of Limosilactobacillus reuteri DSM 17938 for the treatment of acute gastroenteritis in children: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Pediatrics, 14, Article 1941872. https://doi.org/10.3389/fped.2026.1941872

Image Credits: AI Generated

DOI: 10.3389/fped.2026.1941872

Keywords: Limosilactobacillus reuteri DSM 17938, probiotics, acute gastroenteritis, children, diarrhea, meta-analysis, systematic review, pediatrics, GRADE, microbiota, Efficacy, safety

The research focused on children under five years of age, the group in which Campylobacter infections hit hardest. In this age band, diarrheal disease remains a major contributor to illness and death worldwide, and Campylobacter jejuni is frequently implicated alongside better-known culprits such as Salmonella and pathogenic Escherichia coli. Infection typically produces fever, abdominal cramps and bloody or watery diarrhea, and while most cases resolve on their own, severe episodes in malnourished or very young children can demand antibiotic treatment. That is precisely where resistance matters most: when clinicians in resource-limited hospitals must choose a drug empirically, without laboratory guidance, the local resistance landscape determines whether a child recovers quickly or deteriorates while ineffective therapy is administered.

To capture that landscape, the team collected stool samples from children under five presenting with diarrhea at six hospitals in Sana’a: Al Zahrawi Hospital, Algamohory Hospital, Alkowit Hospital, Al-Sabeen Hospital, Al-Thowraha Hospital and Ibn Khaldun Hospital. Samples were processed using culture methods optimized for Campylobacter, a fastidious organism that requires reduced oxygen, elevated carbon dioxide and selective media to grow reliably in the laboratory. Isolates were then subjected to antimicrobial susceptibility testing following standards set by the Clinical Laboratories Standards Institute, using Mueller-Hinton agar as the testing medium. In parallel, the researchers turned to molecular identification, sequencing the 16S rRNA gene, a slowly evolving component of the bacterial ribosome whose sequence serves as a molecular fingerprint for species-level identification, and constructing phylogenetic trees to compare their isolates with reference strains held in international databases.

The headline number from the study is a prevalence of 2.8 percent, with 11 of 389 children testing positive for Campylobacter jejuni. That figure may appear modest, but in the context of a single-city hospital survey of a pathogen that is notoriously difficult to culture, it represents a meaningful baseline for a country that has lacked systematic campylobacteriosis surveillance. The researchers also broke the results down by demographic and behavioral factors, and the patterns that emerged read like a map of transmission routes. Prevalence was higher among girls, at 3.5 percent, and among children aged 36 to 47 months, where it reached 6.2 percent. Children living in rural areas showed a prevalence of 3.5 percent, and infections clustered in the summer months, when 7.2 percent of sampled children in that season carried the bacterium.

The behavioral and environmental associations were particularly telling. Children who had contact with animals showed a prevalence of 4.3 percent, those who drank water from tap sources 5.6 percent, and those who consumed unpasteurized milk 3.7 percent. Each of these routes is well established in the international literature: Campylobacter jejuni colonizes the intestines of poultry, cattle and other animals without making them sick, contaminates water supplies through fecal shedding, and survives in raw milk, where even small doses can cause infection. In Yemen, where household animal keeping is common, municipal water treatment is inconsistent, and unpasteurized dairy remains part of traditional diets, these findings point to concrete, actionable interventions, from hand hygiene after handling animals to water treatment and safer food handling practices.

The antimicrobial results are the study’s most consequential contribution. The isolates displayed high resistance to macrolides, the drug class that includes erythromycin and azithromycin, which are internationally regarded as first-line treatments for severe campylobacteriosis, especially in children, for whom fluoroquinolones are often restricted. High resistance to aminoglycosides was also documented. Macrolide resistance in Campylobacter is particularly worrying because it arises through mutations in the ribosomal target and, once established in a population, tends to persist and spread. In many high-income surveillance systems, macrolide resistance in human Campylobacter isolates remains comparatively low, so the pattern observed in Sana’a signals a local treatment crisis: the drugs most likely to be prescribed for a sick child may simply not work.

By contrast, the isolates remained relatively susceptible to several other agents, with resistance recorded at 18.2 percent for ciprofloxacin, 27.3 percent for tetracycline and 27.3 percent for nalidixic acid. While these figures still represent substantial resistance by global standards, they suggest that, at present, some therapeutic options retain activity against Campylobacter jejuni circulating in Sana’a. The authors caution, however, that susceptibility patterns can shift rapidly under continued antibiotic pressure, and that fluoroquinolone resistance in Campylobacter has risen steeply in many parts of the world following the use of these agents in poultry production. Sustained local susceptibility testing, they argue, is essential to keep empirical treatment guidelines aligned with reality on the ground.

The molecular arm of the study added a layer of confidence that culture alone cannot provide. Sequencing of the 16S rRNA gene confirmed the identity of the isolates as Campylobacter jejuni with sequence identity of at least 99.6 percent against reference sequences, and phylogenetic analysis placed the Yemeni isolates in clusters closely related to established reference strains. This matters for two reasons. First, phenotypic identification of Campylobacter can be ambiguous, and molecular confirmation guards against misclassification that would distort prevalence and resistance statistics. Second, phylogenetic context allows researchers to begin tracing how strains circulate between animals, food, water and humans, a prerequisite for understanding transmission dynamics in a setting where such data have been almost entirely absent. The authors note that future work should employ advanced techniques to detect the antibiotic resistance genes themselves, and should use specialized genetic primers capable of differentiating between Campylobacter subspecies, alongside larger samples drawn from more diverse populations and methods such as multi-locus sequence typing and whole-genome sequencing.

The study was conducted with formal ethical oversight, receiving approval from the Research Ethics Review Committee at the Faculty of Science, Sana’a University under number BM-02-23, dated 11 April 2021, and complying with Yemeni Public Health Law No. 4 of 2009 and the Declaration of Helsinki. Because all participants were children under five, written informed consent was obtained from their parents or legal guardians before enrollment. The research team spanned several Yemeni institutions, including Sana’a University’s Faculty of Science, Hajjah University, Al-Razi University, Al Mahwit University and Ibb University, a collaboration that reflects both the country’s scientific capacity and the logistical challenges of conducting microbiological research amid prolonged instability. The work was published open access, with the article accepted on 21 September 2026 and published on 24 September 2026.

For global health observers, the Sana’a study is a reminder that antimicrobial resistance is not a problem confined to wealthy nations with dense surveillance networks; it evolves wherever antibiotics are used, and it is most dangerous precisely where the capacity to detect it is weakest. The authors close with a call that is as much public health as laboratory science: raising community awareness of hand hygiene after contact with animals, promoting safe food handling, encouraging water treatment, and curbing imprudent antibiotic use. Those measures, combined with expanded epidemiological studies and molecular surveillance, would give Yemeni clinicians something they currently lack, namely an evidence base for treating the youngest and most vulnerable patients with the right drug the first time, while slowing the further march of resistance in a pathogen that thrives at the intersection of animals, water, food and childhood.

Subject of Research: Molecular detection and antimicrobial resistance of Campylobacter jejuni in children with diarrhea in Sana'a City, Yemen

Article Title: Molecular detection and antibiotic susceptibility patterns of Campylobacter jejuni isolated from children under five years in Sana’a City, Yemen

Article References: Al-Thobhani, A., Alghalibi, S. M., Abdullah, Q. Y., Edrees, W. H., Al-Nowihi, M., Al-Arnoot, S., Al-Bana, M. N., Al-Akhali, B., & Al-Shehari, W. A. (2026). Molecular detection and antibiotic susceptibility patterns of Campylobacter jejuni isolated from children under five years in Sana’a City, Yemen. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14520-y

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14520-y

Keywords: Campylobacter jejuni, diarrhea, children under five, antimicrobial resistance, 16S rRNA sequencing, Yemen, Sana'a City, macrolide resistance, foodborne pathogens, public health, phylogenetic analysis, water and food safety

The study, led by Abiot Abera Aydamo of the Ethiopian Institute of Water Resources at Addis Ababa University and Wachemo University, together with Sirak Robele Gari and Seid Tiku Mereta, was designed to overcome a persistent weakness in the childhood diarrhea literature. Most studies in developing countries, including Ethiopia, have relied on cross-sectional surveys that capture a single snapshot in time, making it difficult to distinguish whether risk factors precede illness or merely coincide with it. By following the same households prospectively across seasons and recording each new diarrheal episode as it occurred, the Hosanna team could measure incidence directly and track how exposure to specific hazards translated into disease over time. The research covered three kebeles, the smallest administrative units in Ethiopia, chosen to represent the peri-urban and informal settlements that ring many fast-growing Ethiopian towns.

Data collection combined three complementary methods. Caregivers, primarily mothers, answered a pretested structured questionnaire covering household characteristics, water handling, sanitation, and child care practices. Trained observers conducted spot-check observations of household conditions, a technique that helps verify what families report with what can actually be seen in the home environment, from the cleanliness of water storage containers to the presence of handwashing stations. Finally, a dedicated diarrhea recording questionnaire allowed caregivers to log each episode of illness as it happened, reducing the recall bias that plagues surveys asking parents to remember illnesses weeks or months in the past. This triangulation of self-report, observation, and longitudinal symptom tracking is what gives the study its unusual analytical power for a resource-constrained setting.

On the statistical side, the researchers deployed two modeling approaches. Bivariate logistic regression provided an initial screen of associations, while the core analysis relied on Generalized Estimating Equations, or GEEs. The choice was deliberate and technically meaningful. Where mixed-effects models estimate subject-specific effects, essentially asking how a risk factor changes the trajectory for a particular child, GEEs estimate population-averaged effects, asking how a risk factor shifts the expected disease burden across the whole community. For public health planning, that population-averaged framing is often the more useful one, because interventions such as extending piped networks or running handwashing campaigns operate at the community scale rather than for individual children one at a time. The results were expressed as adjusted incidence rate ratios, or AIRRs, which quantify how much each factor multiplies the rate of diarrheal episodes after accounting for other variables.

The risk factor hierarchy that emerged is striking in its coherence. Children in households with piped water located off the premises, meaning families had to fetch water from taps or standpipes outside the home, experienced 1.57 times the incidence rate of diarrhea compared with children whose homes had water on premises. Unsafe disposal of child stool raised the rate by a factor of 1.47, and children who ate unheated leftover food faced a 1.43-fold increase. The single largest behavioral hazard was poor handwashing by caregivers at critical moments, such as before preparing food, before feeding a child, and after using the latrine or cleaning a child, which was associated with an adjusted incidence rate ratio of 1.95, nearly doubling the rate of illness. Each of these factors represents a well-established pathway by which fecal pathogens travel from the environment into a young child’s mouth, but seeing them quantified together in a single longitudinal cohort, with seasonal coverage, sharpens the picture considerably.

Water quality itself told an equally important story. The team tested household drinking water for Escherichia coli, the standard bacterial indicator of fecal contamination, and found that children drinking contaminated water suffered significantly more diarrhea during both the dry and rainy seasons. That seasonal consistency matters. In many settings, water quality deteriorates dramatically during the rains, when runoff washes waste into shallow wells and unprotected springs, and the rainy season is typically when diarrhea cases surge. But the Hosanna data show that contamination is not merely a wet-weather problem; households drawing E. coli-laden water face elevated risk year-round. This suggests that household water treatment, whether boiling, chlorination, or filtration, could deliver benefits across every season, and that the dry-season contamination likely reflects persistent problems in storage, handling, and source protection rather than episodic weather-driven events alone.

Age emerged as a powerful and protective axis in the analysis. Children aged 24 to 35 months and 36 to 59 months had significantly reduced risk of diarrhea compared with younger children, a pattern consistent with the immunology and behavior of early childhood. Infants and toddlers who are crawling, teething, and exploring their environment by mouth are exposed to far more environmental pathogens, and their immune systems are still naive to the rotating cast of viruses and bacteria that cause gastroenteritis. As children grow older, improved motor control, more adult-like eating habits, and accumulating immunity all push risk downward. The finding reinforces a message that pediatric and water researchers have long emphasized: the window from birth to roughly two years of age is when water, sanitation, and hygiene interventions pay their largest dividends, and it is exactly the window in which the Hosanna cohort shows the heaviest disease burden.

Not all the news in the study is grim. Better hygienic practices were found to be protective against childhood diarrhea, confirming that the behavioral side of the equation works in both directions. Just as poor handwashing at critical times nearly doubles incidence, consistent hygiene practices measurably reduce it. This bidirectional evidence base strengthens the case for hygiene promotion programs that go beyond infrastructure, targeting the specific moments when pathogens are most likely to jump from hands, food, or utensils into a child. The study’s authors argue that improving on-premises water access, promoting mothers’ handwashing at critical times, encouraging household water treatment, and strengthening hygiene and food safety practices are all essential levers for reducing diarrheal disease in settings like Hosanna, and their data provide the incidence estimates and effect sizes needed to model what such interventions might achieve.

The broader significance of the work lies in what it says about peri-urbanization. Hosanna Town, like many secondary cities across Ethiopia and sub-Saharan Africa, is growing faster than its water and sanitation infrastructure can expand. Families settling in informal and peri-urban neighborhoods often live within a few hundred meters of a piped network yet remain unconnected, forced to fetch water in quantities too small for generous hygiene and to store it in containers that invite recontamination. The 2.2 versus 1.0 episodes-per-year contrast between unconnected and connected households is a direct measure of what that infrastructure gap costs in child health. For a disease that remains a leading cause of illness and death among children under five in developing countries, an intervention that halves incidence simply by delivering water to the household tap represents one of the most cost-effective public health opportunities available.

The study received ethical approval from Ethiopia’s National Research Ethics Review Committee under the Ministry of Education and was conducted in accordance with the Declaration of Helsinki, with written consent obtained from the mothers and caregivers of all participating children. It was supported by the Ethiopian Institute of Water Resources at Addis Ababa University and Wachemo University. The authors state that the findings provide evidence to guide interventions aimed at reducing childhood diarrhea in Ethiopia and other developing countries, and the longitudinal design gives that evidence a durability that single-snapshot surveys cannot match. As governments and donors weigh investments in water infrastructure against competing priorities, the Hosanna cohort offers a concrete, quantified answer to a deceptively simple question: what happens to child health when clean water finally reaches the home? The answer, measured episode by episode over a full year of dry seasons and rains, is that the burden of childhood diarrhea drops by half, and the pathogens that stalk the youngest children lose their most reliable ally.

Subject of Research: Incidence and risk factors of diarrhea among under-five children in peri-urban central Ethiopia

Article Title: Incidence of caregiver-reported diarrhea and associated risk factors among under-five children in Hosanna Town, central Ethiopia: a prospective cohort study

Article References: Aydamo, A. A., Gari, S. R., & Mereta, S. T. (2026). Incidence of caregiver-reported diarrhea and associated risk factors among under-five children in Hosanna Town, central Ethiopia: a prospective cohort study. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07776-5

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07776-5

Keywords: diarrhea, under-five children, Ethiopia, piped water, water access, handwashing, E. coli, prospective cohort study, water sanitation and hygiene, child health, peri-urban settlements, food safety

The research team, led by scientists at Shahid Beheshti University of Medical Sciences in collaboration with Hakim Children’s Hospital, collected 79 Shigella isolates from the stool of pediatric patients suffering from diarrhea between September 2023 and April 2025. The children had all been referred to the hospital, one of Tehran’s major pediatric centers, making the sample a representative snapshot of clinically significant infections in the city’s young population. The study was approved by the ethics committee of Shahid Beheshti University of Medical Sciences and funded through a university grant.

Species identification revealed a familiar but shifting landscape. Shigella flexneri remained the predominant species, accounting for 59.5 percent of isolates, while Shigella sonnei made up the remaining 40.5 percent. This distribution matters because the two species differ not only in their epidemiology but also, as the study demonstrated, in their genetic armamentaria and their susceptibility to antibiotics. Globally, S. flexneri has traditionally dominated in low- and middle-income countries while S. sonnei has been more common in industrialized settings, so the near-even split observed in Tehran provides a useful epidemiological marker for a region in epidemiological transition.

The antimicrobial susceptibility testing, performed using the Kirby-Bauer disk diffusion method according to Clinical and Laboratory Standards Institute guidelines, tested isolates against twelve antibiotics. The results were grim. Resistance to ampicillin, a long-standing first-line option, stood at 92.4 percent. Trimethoprim-sulfamethoxazole, another mainstay of treatment in many settings, fared little better, with 91.1 percent of isolates resistant. Tetracycline resistance reached 86.1 percent. These three drugs, which in earlier decades formed the backbone of shigellosis therapy, are now effectively useless against the vast majority of circulating strains.

Not all news was bleak. The majority of isolates remained susceptible to meropenem, a broad-spectrum carbapenem, at 84.8 percent, and to tigecycline, a glycylcycline often held in reserve, at 82.3 percent. These agents thus retain considerable activity against Shigella in this setting, although clinicians must weigh the appropriateness of deploying such broad-spectrum drugs in children, particularly given concerns about preserving these last-line options. More troubling was the species-specific pattern that emerged for other drug classes: S. sonnei isolates demonstrated significantly greater resistance to azithromycin and to the fluoroquinolones than S. flexneri, a difference the authors flagged as statistically significant. Azithromycin and fluoroquinolones such as ciprofloxacin are among the most important oral options for treating shigellosis, so their erosion in S. sonnei narrows the therapeutic window considerably.

Beyond resistance phenotypes, the heart of the study lay in its molecular analysis. The researchers used polymerase chain reaction to screen every isolate for a panel of eleven virulence-related genes, including ipaH, ipaA through ipaD, ipgD, sen, virA, virB, virF, ial, sigA, icsA, and icsB. Many of these genes encode components or effectors of the type III secretion system, a syringe-like molecular apparatus that Shigella uses to inject effector proteins directly into human intestinal epithelial cells. This injection machinery allows the bacterium to invade host cells, escape immune detection, manipulate cell signaling, and spread from cell to cell, producing the colitis and bloody diarrhea characteristic of shigellosis.

The PCR results revealed a strikingly conserved virulence core. Every single one of the 79 isolates carried ipaH, a multicopy gene that is frequently used as a diagnostic target precisely because of its ubiquity and its presence in multiple copies on both the large virulence plasmid and the chromosome. More than 90 percent of isolates also harbored ipaB, ipaC, and ipaD, the genes encoding the invasion plasmid antigens that form the translocation pore and the effector proteins that trigger host cell uptake. The near-universal presence of this core set underscores that the invasive capacity of Shigella remains intact even as the bacterium accumulates resistance determinants; there is no apparent trade-off in which the bacteria sacrifice virulence for resistance.

Not every gene, however, was evenly distributed. The presence of ipgD, which encodes another type III secretion system effector involved in invasion, and sigA, which encodes an enterotoxin contributing to fluid secretion and tissue inflammation, differed significantly between the two species. These species-specific differences in virulence gene carriage suggest that S. flexneri and S. sonnei circulating in Tehran may cause disease through subtly different molecular mechanisms, and they complicate any one-size-fits-all approach to vaccine design or virulence-based diagnostics. A vaccine or therapeutic strategy targeting a single effector might protect against one species but leave the other untouched.

Perhaps the most conceptually significant finding involved the statistical associations between specific virulence genes and resistance phenotypes. The researchers found that resistance to levofloxacin, a fluoroquinolone, was linked to the presence of ipaB, while resistance to ampicillin was associated with ipaD. Even more broadly, sigA was associated with resistance across multiple drug classes. The authors interpret such correlations as evidence that virulence gene profiles could serve as indirect markers of resistance behavior, and they hint at underlying biological or epidemiological mechanisms. Plasmids carrying virulence genes can also carry resistance determinants, and particular genetic lineages that have succeeded in circulating may have acquired both traits together. Co-selection, in which the presence of one trait facilitates the maintenance of another on the same mobile element, is a well-established driver of resistance spread in enteric bacteria, and these associations are consistent with that framework.

The practical implications of the study extend in several directions. For clinicians in Tehran and comparable settings, the near-total loss of ampicillin, trimethoprim-sulfamethoxazole, and tetracycline as treatment options means that empirical therapy must lean increasingly on carbapenems, tigecycline, or whichever oral agents retain activity, decisions that should ideally be informed by species identification and susceptibility testing. For public health authorities, the distinct resistance and virulence profiles of S. flexneri and S. sonnei argue for species-specific surveillance programs that track the two organisms separately rather than lumping them together as generic Shigella. And for researchers, the demonstrated links between virulence genes and resistance phenotypes open a line of inquiry into whether molecular screening for genes such as sigA, ipaB, or ipaD could help predict resistance patterns before culture-based results become available. As the authors conclude, the findings underscore a need for vigilance: in this Tehran pediatric population, shigellosis has become not only a disease of poverty and sanitation but a showcase for how bacterial virulence and antibiotic resistance evolve together in a clinical setting.

Subject of Research: Virulence gene distribution and antimicrobial resistance in pediatric Shigella isolates from Tehran, Iran

Article Title: Distribution of virulence-related genes in Shigella isolates recovered from pediatric patients in Tehran, Iran: association with antimicrobial resistance

Article References: Kazemzadeh Anari, R., Sadredinamin, M., Hashemi, A., Houri, H., Taheri, M., Yousefi Nojookambari, N., Nikmanesh, A., & Ghalavand, Z. (2026). Distribution of virulence-related genes in Shigella isolates recovered from pediatric patients in Tehran, Iran: association with antimicrobial resistance. Gut Pathogens. https://doi.org/10.1186/s13099-026-00875-9

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00875-9

Keywords: Shigella, antimicrobial resistance, multidrug resistance, Shigella flexneri, Shigella sonnei, virulence genes, children, diarrhea, Tehran, type III secretion system, pediatric infectious disease, public health

The research, led by Ethan Gough and Soumya Basu of the Department of International Health at the Johns Hopkins Bloomberg School of Public Health, together with senior author Subhra Chakraborty and colleagues, drew on stool samples and immune measurements from 27 adult volunteers who participated in a controlled clinical trial. Each volunteer received two doses of ACE527, a live attenuated oral ETEC vaccine candidate, and was subsequently challenged with the virulent ETEC strain H10407, a well-characterized isolate that has long served as a benchmark strain in human challenge studies of enteric vaccines. The trial was registered under ClinicalTrials.gov identifier NCT01060748, and the microbiome analysis was approved by the Johns Hopkins University Institutional Review Board under protocol IRB 20100221.

To characterize the bacterial communities living in the participants’ intestines, the team performed 16S ribosomal RNA sequencing on stool samples collected during the trial. This technique amplifies and sequences a molecular marker present in all bacteria, allowing researchers to identify which microbial taxa are present and in what relative abundances, without needing to culture the organisms in the laboratory. From these data the investigators computed two standard measures of community structure: alpha diversity, which captures how many species are present and how evenly distributed they are within a single sample, and beta diversity, which measures how similar or different microbial communities are between individuals or across time points.

The immune outcomes of interest were drawn from enzyme-linked immunosorbent assay measurements of antibody responses directed against two key ETEC antigens: the B subunit of heat-labile toxin, known as LTB, and colonization factor antigen I, or CFA/I, a surface structure the bacteria use to adhere to the intestinal lining. Antibodies were quantified both in serum, reflecting systemic immunity, and in the antibody-in-lymphocyte-supernatant assay, or ALS, which captures antibodies secreted by circulating plasmablasts and serves as a surrogate for mucosal immune activation in the gut. Both IgG and IgA classes were measured, with IgA of particular interest because it is the dominant antibody isotype at mucosal surfaces and is widely regarded as a correlate of protection against intestinal pathogens.

The statistical analysis went well beyond simple comparisons. The team used regression models to link individual bacterial taxa to immune readouts, applied the Microbiome Regression-Based Kernel Association Test, known as MiRKAT, to test whether overall community composition predicted immune responses, and employed a relaxed least absolute shrinkage and selection operator, or LASSO, approach to identify parsimonious sets of taxa associated with protection. Protection itself was assessed clinically, based on whether volunteers developed severe diarrhea and on whether ETEC could be detected as colonizing the gut after the challenge with H10407.

One of the clearest signals emerged from the alpha diversity analysis. Volunteers with higher inverse-Simpson diversity, a metric that increases both with the number of species present and with their evenness, tended to mount weaker ALS IgA responses against both LTB and CFA/I. In other words, a more diverse gut community was associated with a blunted mucosal antibody response to the vaccine. This finding is intriguing because it runs counter to the common assumption that greater microbial diversity is inherently beneficial; in the specific context of oral live attenuated vaccine immunogenicity, a densely populated and diverse intestinal ecosystem may compete with the vaccine strain or modulate innate immune signaling in ways that dampen the antigen-specific response.

Beta diversity told a different story. The overall composition of the gut community, considered as a whole, correlated with increased serum anti-CFA/I IgA, suggesting that the identity of the microbes present, rather than simply their number, shapes the systemic arm of the antibody response. At the level of individual taxa, the vaccination series was associated with a measurable increase, on the order of 25 to 30 percent, in the relative abundance of several groups, including the Eubacterium brachy group, members of Family XIII AD3011, and Actinomyces. Whether these shifts represent a direct effect of vaccine colonization on the ecosystem or an indirect consequence of the immune activation that vaccination triggers remains an open question, but the consistency of the direction of change across participants suggests a reproducible vaccine-microbiome interaction.

Perhaps the most consequential findings concerned specific bacterial families whose abundance tracked with protection. Members of Anaerovoraceae, Peptostreptococcaceae, Oscillospiraceae, and Veillonellaceae were associated with enhanced immune responses and, importantly, with protection against severe diarrhea and against ETEC colonization following the challenge. In contrast, several other groups, including Ruminococcaceae, Sutterellaceae, Coriobacteria, Clostridia, and Actinobacteria, showed antagonistic associations, being linked in the opposite direction with immune outcomes or protection. These antagonistic taxa are not necessarily harmful in their own right; the associations are statistical relationships that require mechanistic follow-up. Nonetheless, the pattern suggests that the interplay between a person’s resident microbiota and an oral vaccine is not uniform across the microbial community but instead involves specific lineages that either support or hinder the generation of protective immunity.

The implications for vaccine development are considerable. Oral live attenuated vaccines must survive passage through the stomach, establish limited replication in the intestine, and present their antigens to the gut-associated lymphoid tissue, and every one of those steps occurs in the context of a complex microbial ecosystem that can facilitate or obstruct them. If the microbiome modulates take of the vaccine strain, the magnitude of mucosal IgA responses, or the likelihood of sterilizing protection after exposure to wild-type bacteria, then microbiome status may help explain a long-standing puzzle in ETEC vaccine research: why candidate vaccines that perform reasonably well in controlled human challenge studies among adults in industrialized settings often show weaker immunogenicity and efficacy when tested in infants and young children in endemic countries, whose gut communities differ markedly from those of the trial volunteers in Baltimore.

The authors emphasize that the study, funded by the National Institute of Allergy and Infectious Diseases through grants R01AI153399 and R56AI168316 and additionally supported by the PATH agreement GAT.1371-05689-CTA, is an early step in a longer research program. With 27 participants, the analysis is necessarily exploratory, and associations identified through sequencing and regression modeling will need to be validated in larger and more diverse cohorts, ideally including populations in ETEC-endemic regions where the public health burden is greatest. Still, the work offers a concrete roadmap: specific taxonomic markers, measurable by inexpensive 16S sequencing, could eventually help researchers stratify volunteers in vaccine trials, stratify risk in endemic populations, or even guide the rational use of microbiome-directed adjuncts such as targeted prebiotics to maximize the protective potential of future ETEC vaccines. As enteric vaccine science matures, it appears increasingly clear that the answer to whether a vaccine works may lie not only in the vaccine itself but in the trillions of microbes with which it shares the intestine.

Subject of Research: How gut microbiota composition influences immune responses and protection following oral ETEC vaccination and challenge

Article Title: Influence of gut microbiota on immune responses and protection in volunteers receiving the live attenuated oral ETEC vaccine ACE527 followed by virulent ETEC H10407 challenge

Article References: Gough, E., Basu, S., Brubaker, J., DeNeraing, B., Sack, D., Bourgeois, A. L., Walker, R., Harro, C. D., & Chakraborty, S. (2026). Influence of gut microbiota on immune responses and protection in volunteers receiving the live attenuated oral ETEC vaccine ACE527 followed by virulent ETEC H10407 challenge. Gut Pathogens. https://doi.org/10.1186/s13099-026-00878-6

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00878-6

Keywords: ETEC, gut microbiota, ACE527 vaccine, H10407 challenge, IgA response, mucosal immunity, 16S rRNA sequencing, diarrhea, vaccine immunogenicity, microbiome diversity, Influence, microbiota

Spleen deficiency with dampness pattern diarrhea is a diagnosis rooted in traditional Chinese medicine that overlaps substantially with chronic functional diarrhea and diarrhea-predominant irritable bowel syndrome as understood in Western medicine. In traditional medical theory, the condition arises when the digestive system loses its capacity to transform and transport fluids, producing loose stools, fatigue, poor appetite, and abdominal discomfort. Clinically, Weiling Decoction has been used for such patients for years, but the pharmacological basis of its effects has remained poorly characterized. The new study set out to close that gap by combining modern analytical chemistry with high-throughput genomic sequencing.

The research team, led by corresponding author Ying Cai, first established a mouse model of the syndrome by exposing Kunming mice to high-humidity environments and administering oral lard, a combination designed to replicate the cold, damp conditions and dietary factors associated with the disorder. The team then turned to an ultra-high-performance liquid chromatography tandem mass spectrometry workflow, known as UHPLC-MS/MS, to chemically fingerprint Weiling Decoction. This analysis identified twenty primary bioactive compounds in the formula, including vicenin-1, inosine, and chlorogenic acid, each of which has documented anti-inflammatory or metabolic activity in previous literature.

With the chemical profile in hand, the researchers evaluated how the formula performed therapeutically. Histological examinations of small intestinal tissue revealed that treated mice showed a marked restoration of villus length, the finger-like projections that absorb nutrients in the gut and are often damaged or shortened in diarrheal disease. Treated animals also exhibited a higher density of goblet cells per unit area, specialized cells that produce the protective mucus layer lining the intestinal wall. These structural changes suggest that the decoction does more than suppress symptoms; it appears to actively support the repair and maintenance of the intestinal mucosal barrier.

Biochemical assays reinforced the picture of a remedy that rebalances disrupted signaling networks. Serum levels of cyclic adenosine monophosphate, or cAMP, a molecule central to regulating fluid secretion in the gut, rose in treated mice alongside increases in D-xylose, a marker of intestinal absorptive capacity, and gastrin, a hormone that stimulates digestive function. Meanwhile, levels of cyclic guanosine monophosphate, or cGMP, and vasoactive intestinal peptide, or VIP, both of which promote intestinal secretion and can exacerbate diarrhea when overproduced, were reduced. Together these shifts indicate that the formula helps recalibrate what the researchers describe as the gastrointestinal-water-energy regulatory network, a coordinated system of hormonal and second-messenger signals that governs how the gut manages fluids and energy.

The heart of the study lies in its microbiome analysis. Using 16S rRNA gene sequencing, the researchers surveyed the bacterial populations in the small intestinal contents of the mice and found that treatment with Weiling Decoction significantly increased the relative abundance of three bacterial genera: Limosilactobacillus, Dwaynesavagella, and Paramuribaculum. Limosilactobacillus, a genus that includes well-known probiotic species, has been repeatedly linked to gut barrier protection and anti-inflammatory effects. Shifts in these bacterial populations suggest the decoction works in part by nurturing a microbial community better equipped to maintain intestinal homeostasis.

To probe what these microbial changes might mean functionally, the team applied PICRUSt2, a computational tool that predicts the metabolic capabilities of microbial communities based on their genetic profiles. The analysis pointed to secondary bile acid biosynthesis as a potentially critical mechanistic pathway. Secondary bile acids are produced when gut bacteria chemically modify the bile acids released by the liver, and a growing body of research links these microbial metabolites to intestinal immune regulation, epithelial barrier integrity, and metabolic signaling. The finding is consistent with recent work showing that gut symbionts can alleviate metabolic and inflammatory disease through secondary bile acid pathways, and it places Weiling Decoction’s effects within a rapidly expanding framework of microbiome-mediated pharmacology.

The study’s authors are careful to frame their findings as correlative rather than definitively causal, noting that the results suggest a microbiota-associated pharmacological mechanism rather than proving one outright. Direct evidence that transplanting the altered microbiota reproduces the therapeutic effect, for instance through fecal microbiota transplantation experiments, remains a logical next step. Nonetheless, the convergence of histological repair, biochemical normalization, and microbial restructuring in the same animals provides a coherent and testable model for how the formula may exert its clinical effects.

From a broader perspective, the research speaks to a growing scientific interest in what traditional Chinese medicine practitioners call syndrome-matched treatment, the idea that therapies should be tailored not just to a disease label but to the specific pattern of dysfunction an individual patient exhibits. By characterizing both the chemical constituents of Weiling Decoction and the molecular and microbial consequences of its administration, the study provides what the authors describe as a biotechnological basis for such syndrome-targeted approaches to gastrointestinal disorders. The data underlying the microbiome analysis have been deposited in the NCBI Sequence Read Archive under accession number PRJNA1346698, allowing other researchers to scrutinize and extend the findings.

Chronic diarrhea remains a substantial global health burden, and conventional treatments often manage symptoms without addressing the underlying disruptions in gut ecology and signaling that drive recurrence. If the mechanisms identified in this mouse model hold up in further studies, including controlled human trials, Weiling Decoction could offer a template for developing microbiome-directed therapies that restore gastrointestinal function by working with, rather than against, the body’s resident microbial communities. For now, the study stands as a compelling example of how modern analytical tools, from mass spectrometry to gene sequencing, can illuminate the biological logic hidden within traditional remedies and potentially translate ancient clinical wisdom into the pharmacological language of the twenty-first century.

Subject of Research: Weiling Decoction alleviates spleen deficiency with dampness pattern diarrhea through modulation of intestinal microbiota

Article Title: Integrated UHPLC–MS/MS and 16S rRNA sequencing reveals that Weiling Decoction alleviates spleen deficiency with dampness pattern diarrhea by modulating intestinal microbiota

Article References: Yu, D., Long, Q., Tian, Q., Zhang, X., Li, D., Tan, Z., & Cai, Y. (2026). Integrated UHPLC–MS/MS and 16S rRNA sequencing reveals that Weiling Decoction alleviates spleen deficiency with dampness pattern diarrhea by modulating intestinal microbiota. 3 Biotech, 16(10), Article 421. https://doi.org/10.1007/s13205-026-05052-y

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05052-y

Keywords: Weiling Decoction, traditional Chinese medicine, intestinal microbiota, diarrhea, 16S rRNA sequencing, UHPLC-MS/MS, spleen deficiency with dampness pattern, secondary bile acids, gut barrier, PICRUSt2, Limosilactobacillus, gastrointestinal health